Skip to main content

Table 1 Demographic and clinical data

From: Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria

Patient

Sex/Age, years

Histology

Cycle of chemotherapy

mRECIST outcome at the end of chemotherapy

Evaluation of the response to chemotherapy

1

M/72

Epitheloid

1

PD

PD

2

F/71

Biphasic

1

PD

PD

3

M/52

Epitheloid

2

PD

PD

4

M/62

Epitheloid

1

PD

PD

5

M/73

Epitheloid

1

ST

DC

6

F/75

Epitheloid

4

PR

DC

7

M/58

Epitheloid

1

ST

DC

8

M/75

Epitheloid

1

PR

DC

9

F/46

Biphasic

1

ST

DC

10

M/61

Epitheloid

1

ST

DC

11

M/67

Sarcomatoid

2

ST

DC

12

M/60

Epitheloid

1

ST

DC

13

M/75

Epitheloid

1

ST

DC

14

M/68

Epitheloid

2

PD

PD

15

M/84

Epitheloid

1

PD

PD

16

M/60

Epitheloid

1

ST

DC

17

M/72

Epitheloid

2

ST

DC

18

M/80

Epitheloid

1

ST

DC

19

M/67

Epitheloid

4

ST

DC

  1. mRECIST = modified Response Evaluation Criteria in Solid Tumors, PD = progressive disease, ST = stable disease, PR = partial response, DC = disease control